Vicore Pharma Holding Stock Current Ratio
| VICO Stock | SEK 7.91 0.13 1.67% |
Vicore Pharma Holding fundamentals help investors to digest information that contributes to Vicore Pharma's financial success or failures. It also enables traders to predict the movement of Vicore Stock. The fundamental analysis module provides a way to measure Vicore Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vicore Pharma stock.
Vicore |
Vicore Pharma Holding Company Current Ratio Analysis
Vicore Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Vicore Pharma Current Ratio | 19.83 X |
Most of Vicore Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vicore Pharma Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Vicore Pharma Holding has a Current Ratio of 19.83 times. This is much higher than that of the Healthcare sector and 183.29% higher than that of the Biotechnology industry. The current ratio for all Sweden stocks is notably lower than that of the firm.
Vicore Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vicore Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vicore Pharma could also be used in its relative valuation, which is a method of valuing Vicore Pharma by comparing valuation metrics of similar companies.Vicore Pharma is currently under evaluation in current ratio category among its peers.
Vicore Fundamentals
| Return On Equity | -0.99 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 81.85 M | |||
| Shares Owned By Insiders | 16.14 % | |||
| Shares Owned By Institutions | 51.89 % | |||
| Price To Earning | 163.82 X | |||
| Price To Book | 8.67 X | |||
| EBITDA | (293.13 M) | |||
| Net Income | (296.48 M) | |||
| Cash And Equivalents | 215.97 M | |||
| Cash Per Share | 5.10 X | |||
| Total Debt | 320 K | |||
| Current Ratio | 19.83 X | |||
| Book Value Per Share | 2.24 X | |||
| Cash Flow From Operations | (265.17 M) | |||
| Earnings Per Share | (4.76) X | |||
| Target Price | 69.6 | |||
| Number Of Employees | 23 | |||
| Beta | 0.59 | |||
| Market Capitalization | 1.26 B | |||
| Total Asset | 451.17 M | |||
| Net Asset | 451.17 M |
About Vicore Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vicore Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vicore Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vicore Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.